Jamieson is delighted to announce that it has advised the management team of LGC on KKR’s sale of the business to Cinven and Astorg.

LGC is one of the largest private Life Science Tools companies in the world, providing tools for quality assurance and genomics applications in a range of sectors, including human healthcare and applied markets. The company is headquartered in London and has over 3,200 employees with operations across 22 countries.

The Jamieson team, led by Stuart Coventry and Andrew Cox, advised Tim Robinson (CEO) and his team on their reinvestment alongside the acquiring consortium, as well as the terms of the equity incentive programme to be implemented in the new holding structure.

Jamieson previously advised the team on KKR’s acquisition of the business from Bridgepoint in 2016.

Jamieson is pleased to announce that it has advised the management team of Horizon on the sale of the business to Graphite Capital from Stage Capital. Graphite Capital will work alongside the management team to help grow and expand the business and deliver their long term vision.

Paul Callander, CEO said “Jamieson and the team, led by Tom Burton & Laura Yell provided excellent advice to myself and the management team which helped us in the midst of a complicated and detailed process to add clarity and advice which proved to be vital in the context of the deal.’

Tom Burton and Laura Yell advised Chief Executive Paul Callander and the senior management team on their reinvestment in the new structure as well as the terms of the new management equity incentive.

Horizon is a leading provider of specialist Residential care, Education and Transitional Leaving Care Services for children and young adolescents, managing 50 residential homes, fourteen-day school sites and over 360 supported living flats across England.

Jamieson is pleased to announce that it has advised the management team of Outcomes First Group on its acquisition by Stirling Square from Sovereign Capital.

Outcomes First Group is a leading specialist education and care provider for children and adults with autism, complex needs, learning disabilities and social, emotional and mental health difficulties (SEMH).  The Group, operating as 3 divisions, delivers services to around 750 individuals in over 100 local authorities across the UK.

Ian Jamieson, David Kirkpatrick and Daniel Meschaninov advised the management team on the commercial terms of their participation in the deal.

Jamieson is pleased to announce that it has advised David Hillier (CEO) and the management team of Independent Vetcare Group International (IVC) during EQT’s sale of a minority stake in the business to Nestlé and a number of financial investors.

IVC operates a network of over 1,100 veterinary clinics and hospitals across Europe as well as an online pet pharmacy. Jamieson previously advised the management team during the acquisition of the business by EQT from Summit Partners at the end of 2016 and on the subsequent integration of Evidensia, an existing EQT portfolio company, in early 2017.

Stuart Coventry and Gus Gayford of Jamieson advised the management team on the commercial terms of their participation in the deal.

Jamieson is delighted to announce that it has advised the management team of Sterling Pharma Solutions (“Sterling”) on its acquisition by GHO Capital, the European specialist investor in healthcare.

Headquartered in Newcastle upon Tyne, UK, Sterling is a leading provider of API development and manufacturing, with a reputation for world class quality standards. This is reflected in Sterling’s long-term relationships with blue-chip pharmaceutical and animal health clients, as well as a strong track record with global regulators including the FDA and EMA. Sterling delivers a full-service offering of API development and GMP manufacturing to support its customers throughout the entire product lifecycle.

Sterling CEO, Kevin Cook, commented: “It was very reassuring to be supported by the Jamieson team. Their knowledge and experience helped us efficiently navigate a complex process. The advice and guidance we received resulted in a successful outcome“

The Jamieson team of Tom Burton and Ross Wheeler advised CEO Kevin Cook, CFO Tushar Jain, and the rest of the team during a competitive process on the terms of the transaction and the management incentive arrangements proposed by their new owner.

Jamieson is pleased to announce it has advised Jeanine Lemmens (CEO), Ron Kevanaar (CFO) and the management team of KidsFoundation on its acquisition from Onex. KidsFoundation is the largest childcare provider in the Netherlands providing childcare for more than 30,000 children across 281 centres.

As part of the transaction H.I.G, which invested in the business in 2014, will exit its investment.

The Jamieson team comprised Stuart Coventry, David Kirkpatrick and Gus Gayford.

Jamieson is pleased to have been able to advise the Alcaliber management team on the sale from Torreal and Sanofi to new owners GHO Capital. Alcaliber is a leading independent supplier of Active Pharmaceuticals Ingredients to the global pharmaceutical industry. The Company is headquartered in Spain and has a 45-year track record of best-in-class industrial operations in a tightly regulated subsector niche with high barriers to entry. Alcaliber and its specialist subsidiary, Linneo Health, are sector leading businesses with state of the art production facilities and a reputation for quality of product resulting in stable, sustainable growth.

The team from Jamieson was led by Jose Basabe, supported by Ross Wheeler and Pippa Knowles

Jamieson is pleased to announce that it has advised the management team of Mater Private Healthcare on its acquisition by Infravia Capital.

Mater Private Healthcare is the leading acute healthcare infrastructure group in Ireland and currently operates two major acute hospitals, in Dublin and Cork, two advanced Cancer Centres in Limerick and Liverpool and a number of out-patient clinics in various locations throughout Ireland. Since inception in 1986, Mater Private has offered some of the most technologically advanced treatment options for patients and has pioneered many major innovative developments in the delivery of healthcare in Ireland.

Mater Private Healthcare’s CEO, John Hurley, commented: “Working with Infravia will allow us to develop our facilities and services, and significantly expand our services to meet the needs for Ireland’s growing population.”

The Jamieson team of Stuart Coventry, Stephen Maxwell and Jack Yang advised John Hurley and the team on the terms of the transaction and their reinvestment alongside Infravia.

Jamieson is delighted to announce that it has advised Rachael Wyllie and the management team of CRF Health on the acquisition of the business by Genstar Capital from Vitruvian Partners. As part of the transaction, CRF will be combined with Bracket, a Genstar portfolio company. The transaction is expected to complete by the end of 2018 and is subject to customary closing and regulatory approvals.

CRF Health is the leading provider of eSource technology solutions for the life sciences industry. The business has experience in more than 800 clinical trials across 74 countries. The management team has delivered excellent financial growth in recent years.

Rachael Wyllie, CEO of CRF Health and Executive Chairman of the combined group commented: "This is an exciting step forward for patients, clients, and our new combined team. The complementary nature of the two businesses provides us with the platform and scale for future growth in our dynamic markets, while ensuring our customers have more access to the latest patient-centric innovations in clinical research."

The Jamieson team of Ian Jamieson, Stephen Maxwell and Gus Gayford advised the CRF team on the transaction and the management incentive arrangements to be implemented under Genstar’s majority ownership.

Jamieson is delighted to announce that it has advised the management team of Portman Dental Care, led by Sam Waley-Cohen (Founder and CEO), on Core Equity’s acquisition of a majority stake in the business.

Portman was established in 2009 and has grown rapidly, with over 75 dental practices at time of writing. The company focuses on the private dental market in the UK and has a proven track record of growth through the successful acquisition and integration of independent practices.

As part of the transaction, Livingbridge, which first invested in Portman in 2014, will fully exit its investment.

The Jamieson team, led by Stuart Coventry and Gus Gayford, advised Sam Waley-Cohen and the Portman management team on their reinvestment alongside Core Equity and equity incentive arrangements in the new structure.